skinny.

Latest / Taylor Tailored

Lilly Says Its New Obesity Pill Beat High-Dose Oral Semaglutide — But The Comparison Has A Catch

Eli Lilly says Foundayo, its once-daily oral GLP-1 medicine, produced greater weight loss and better blood-sugar control than 25 mg oral semaglutide in adults with type 2 diabetes. The headline sounds like a direct victory, but the evidence is more nuanced.

This episode explains the Foundayo vs oral semaglutide comparison, the differences between the ACHIEVE-3 and PIONEER PLUS trials, the reported weight and A1C results, and why an indirect statistical comparison is not the same as a randomised head-to-head study. It also looks at Foundayo’s practical dosing advantage, its FDA-approved…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.